Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
CKS Topic Review: Type 2 diabetes

Source: Clinical Knowledge Summaries (CKS)

Date published: 20/10/2009 15:53

Summary
by: Nicola Pocock

This Topic Review is based on the NICE guideline ‘Type 2 diabetes: the management of type 2 diabetes (update)’, the short guideline ‘Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes’ and the guideline ‘Type 2 diabetes: prevention and management of foot problems’.  It covers the management of glucose control and cardiovascular risk in people with Type 2 diabetes, and the management of the complications associated with Type 2 diabetes.

 

The target audience is healthcare professionals working within the NHS in England, and providing first contact or primary health care. Please see the link below for details.

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Related evidence
2: Cardiovascular system
05/02/2012
Tranexamic acid for upper gastrointestinal bleeding
05/02/2012
Pentoxifylline for intermittent claudication
02/02/2012
Bezafibrate for primary biliary cirrhosis
6.1.2 Antidiabetic drugs
17/01/2012
SMC accepts linagliptin film-coated tablet (Trajenta®) for restricted use
17/01/2012
SMC accepts once-weekly exenatide (Bydureon®) for restricted use
12/01/2012
AWMSG issues Final Appraisal Recommendation on the use of saxagliptin (Onglyza®) for the treatment of type 2 diabetes mellitus
Diabetes
17/01/2012
SMC accepts linagliptin film-coated tablet (Trajenta®) for restricted use
17/01/2012
SMC accepts once-weekly exenatide (Bydureon®) for restricted use
12/01/2012
AWMSG issues Final Appraisal Recommendation on the use of saxagliptin (Onglyza®) for the treatment of type 2 diabetes mellitus
Hyperlipidaemia
19/01/2012
AWMSG issues Final Appraisal Recommendation on rosuvastatin (Crestor®)
11/10/2011
Scottish Medicines Consortium does not recommend rosuvastatin (Crestor®) for use in NHS Scotland for prevention of major cardiovascular events
11/07/2011
Statins for acute coronary syndrome
Hypertension
21/10/2011
Evening versus morning dosing regimen drug therapy for hypertension
11/10/2011
Scottish Medicines Consortium accepts Sevikar HCT® (olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide) for use in NHS Scotland
11/10/2011
Scottish Medicines Consortium accepts Sevikar HCT® (olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide) for use in NHS Scotland
Back